A share price of Centessa Pharmaceuticals plc ADR [CNTA] is currently trading at $17.50, up 4.48%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The CNTA shares have gain 3.55% over the last week, with a monthly amount glided 3.24%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Centessa Pharmaceuticals plc ADR [NASDAQ: CNTA] stock has seen the most recent analyst activity on September 20, 2024, when Morgan Stanley upgraded its rating to a Overweight and also boosted its price target to $26 from $11. Previously, B. Riley Securities started tracking the stock with Buy rating on September 19, 2024, and set its price target to $33. On July 18, 2024, Oppenheimer initiated with a Outperform rating and assigned a price target of $14 on the stock. Jefferies upgraded its rating to a Buy and increased its price target to $11 on November 15, 2023. Morgan Stanley upgraded its rating to a Equal-Weight and raised its price target to $8 on October 26, 2023. In a note dated June 12, 2023, Guggenheim initiated an Buy rating and provided a target price of $9 on this stock.
Centessa Pharmaceuticals plc ADR experienced fluctuations in its stock price throughout the past year between $6.65 and $18.97. Currently, Wall Street analysts expect the stock to reach $23.25 within the next 12 months. Centessa Pharmaceuticals plc ADR [NASDAQ: CNTA] shares were valued at $17.50 at the most recent close of the market. An investor can expect a potential return of 32.86% based on the average CNTA price forecast.
Analyzing the CNTA fundamentals
Gross Profit Margin for this corporation currently stands at 0.9% with Operating Profit Margin at -23.43%, Pretax Profit Margin comes in at -22.95%, and Net Profit Margin reading is -23.37%. To continue investigating profitability, this company’s Return on Assets is posted at -0.26, Equity is -0.52 and Total Capital is -0.28. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.17.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 16.90 points at the first support level, and at 16.31 for the second support level. However, for the 1st resistance point, the stock is sitting at 17.80, and for the 2nd resistance point, it is at 18.11.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Centessa Pharmaceuticals plc ADR [NASDAQ:CNTA] is 21.52. Also, the Quick Ratio is 21.52, while the Cash Ratio stands at 14.96. Considering the valuation of this stock, the price to sales ratio is 333.44, the price to book ratio is 4.62.
Transactions by insiders
Recent insider trading involved Weinhoff Gregory M, Chief Business Officer, that happened on Dec 26 ’24 when 10000.0 shares were sold. Officer, Weinhoff Gregory M completed a deal on Dec 26 ’24 to buy 10000.0 shares. Meanwhile, Chief Executive Officer SAHA SAURABH sold 55000.0 shares on Dec 20 ’24.
